A Renal Impairment Study for PF-04965842
Public ClinicalTrials.gov record NCT03660241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN SUBJECTS WITH RENAL IMPAIRMENT AND IN HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).
Study identification
- NCT ID
- NCT03660241
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2018
- Primary completion
- Nov 4, 2019
- Completion
- Nov 4, 2019
- Last update posted
- Mar 21, 2022
2018 – 2019
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami Division of Clinical Pharmacology | Miami | Florida | 33136 | — |
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Orlando Clinical Research Center | Orlando | Florida | 32809 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Renal Impairment trials
Other public records listing Renal Impairment. Sorted by last update posted; newest first. Not a recommendation.
- NCT07426380: A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function Active, not recruiting
- NCT07559396: A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease Recruiting
- NCT07315360: A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function Recruiting
- NCT06911320: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Recruiting
- NCT07348237: A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) Recruiting
- NCT07017933: Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03660241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2022 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03660241 live on ClinicalTrials.gov.